Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Liuqing Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China. Hauptthemen laut MEDLINE: Pyrazoles, Benzofurans, Antineoplastic Agents, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: University Natural Science Research Project of Anhui Province, Major Science and Technology Projects in Anhui Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Targeting the 'undruggable' MYC oncogene remains a challenging objective. Despite substantial research efforts, a majority of MYC direct inhibitors discovered so far lack in vivo efficacy. Herein, benzofuranyl-pyrazole has been identified as a structurally novel scaffold directly disrupting MYC function. Among the final compounds, 15 displayed 10-fold enhanced antiproliferative activity over MYCi975, a well-established MYC inhibitor, against PC-3 cells. Besides, it exhibited low micromolar to submicromolar activities against 14 other neoplastic cell lines. Its direct perturbation of MYC function was confirmed by the obstruction of MYC/MAX interaction in Co-IP and AlphaLISA assays. Moreover, it decreased MYC thermal stability, triggered MYC degradation, and impaired expression of MYC-responsive luciferase. Notably, 15 potently delayed tumor growth and outperformed MYCi975 in a mouse allograft model, even when administered every other day. Meanwhile, it synergized with a small-molecule immune checkpoint inhibitor in vivo, highlighting its potential application in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
- iCarbonX (Shenzhen) Co., Ltd., Shenzhen 518000, China.
- Department of Medicinal Chemistry, Anhui Academy of Chinese Medicine, Hefei 230012, China.
- Anhui Province Key Laboratory of Bioactive Natural Products, Hefei 230012, China.
ORCID-Profile: Wenhu Zhan, Yang Wang, Xiaodong Ma
Förderung
- University Natural Science Research Project of Anhui Province
- Major Science and Technology Projects in Anhui Province
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Yang, L., Zuo, H., Sha, M., Zhan, W., Li, J., Liu, Y., Fang, F., Wang, Y., & Ma, X. (2025). Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01307
Vancouver
Yang L, Zuo H, Sha M, Zhan W, Li J, Liu Y, et al. Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01307
BibTeX
@article{Yang2025,
author = {Yang, Liuqing and Zuo, Haojie and Sha, Mengdie and Zhan, Wenhu and Li, Jiaming and Liu, Yulei and Fang, Fang and Wang, Yang and Ma, Xiaodong},
title = {Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01307}
}
EUVIMED